The 2025 annual European Alliance of Associations for Rheumatology (EULAR) Congress recently concluded in Barcelona, Spain. The conference ran from June 11 through June 14, 2025. For the previous two years, conference attendance was well over 12,000 rheumatologists and other health professionals. Thanks to the massive annual turnout, the volume of research presented at the EULAR Congress is always impressive, and 2025 was no different.

Below is a selection of posters from the 2025 EULAR Congress, for your convenience. Visit the event’s official website to view more. 

Clinical Outcomes Of A Multidisciplinary Approach In Patients With Interstitial Lung Disease In Anti-neutrophil Cytoplasm Antibody-Associated Vasculitides: A Real-world Monocentric Prospective Study

  • Description: The study sought to explore the radiological features and clinical characteristics of antineutrophil cytoplasmic antibodies-associated vasculitides interstitial lung disease (AAV-ILD), as well as explore the impact of multidisciplinary management for affected patients.
  • Result: Research suggests that a prompt evaluation and early treatment from rheumatologists and pulmonologists is associated with good clinical outcomes regarding ILD progression and steroid sparing effect.

Risk Of 90-day Heart Failure Readmission Among Patients With Rheumatoid Arthritis: A Retrospective Cohort Study

  • Description: Researchers aimed to ascertain the incidence and any risk factors associated with 90-day readmission for heart failure in patients with rheumatoid arthritis who were hospitalized for heart failure.
  • Result: Patients who develop heart failure have a higher incidence of 90-day readmission for heart failure, than the general heart-failure population in the cohort.

Increased Risk For Cardiac And Vascular Morbidity In Giant Cell Arteries (GCA): Large-scale Propensity-matched Global Retrospective Cohort Study

  • Description: This study assessed the risk of death and cardiovascular outcomes in giant cell arteries using a global electronic database for biomedical and clinical research.
  • Result: Overall, the risk of death and cardiovascular events increased in patients with giant cell arteries, with and without polymyalgia rheumatica and in clinically pure polymyalgia rheumatica. Cerebrovascular events increased in patients with giant cell arteries with or without polymyalgia rheumatica.

Mortality Rates And Causes Of Death Among Patients With Systemic Lupus Erythematosus – The Forward Lupus Registry

  • Description: The study was focused on describing mortality rates and primary causes of death in individuals with systemic lupus erythematosus and consider prognostic factors influencing mortality.
  • Result: Cardiovascular disease emerged as the leading cause of death, along with noted disparities in higher mortality rates among male patients of Black ethnicity.

Analysis And Validation Of The Different Progressive Pulmonary Fibrosis (PPF) Criteria In A Cohort Of Patients With Interstitial Lung Disease Associated To Systemic Sclerosis

  • Description: Interstitial lung disease associated with systemic sclerosis (SSc-ILD) affects the majority of patients and is a leading cause of death in most clinical series. The long-term prognosis of SSc-ILD patients who progress in the first year have not been established for all criteria.
  • Result: The application of criteria in routine clinical practice should strike a balance between an early detection of progression and identify a higher long-term mortality. 
Reducing Cardiovascular Risk In Myositis: A Focus On Lipid-lowering Therapy
  • Description: The goal of the study was to assess cardiovascular risk in a myositis cohort (using the SCORE-2 prediction system, carotid artery Doppler ultrasound measurement, and biomarkers), recommend lipid-lowering treatment, and follow the efficacy and adverse events for a six-month treatment period.
  • Result: Cardiovascular risk of patients with myositis is high, but carefully applied lipid-lowering treatment is key to reducing risk. 

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, all rights reserved.